Full-Time

QA Executive Level III

Posted on 3/18/2025

Viatris

Viatris

10,001+ employees

Global healthcare company providing medicines access

No salary listed

Senior

Minna, Inverin, Co. Galway, Ireland

Category
QA & Testing
Quality Assurance
Requirements
  • Minimum of a Bachelor's degree (or equivalent) in a Science or engineering related discipline
  • At least 5 years relevant experience within a relevant sector (i.e pharmaceutical/medical device industry)
  • Minimum of 3 years’ experience within a Quality Assurance role
  • Experience of all quality system aspects including: Deviation management, CAPA, complaint handling, auditing, change management, supplier qualification, and batch release
  • Excellent communication (oral & written) and presentation skills
  • Ability to handle multiple tasks in a fast paced environment with strong organisational and time management skills
  • Experience of working with various IT systems and software packages with strong working knowledge of Microsoft Office (Word, Excel, Powerpoint etc.)
Responsibilities
  • Lead specific Quality management system elements such as GMP investigations, Change Control, CAPA and Risk Assessment and Customer Quality Complaints/Medical Device Vigilance systems
  • Support the Qualified person(s) to lead and perform data review audits (Batch Production Records, Validation Documents and Development Documentation, Quality Control Data as required)
  • Support the Quality Manager in the definition and maintenance of the annual internal and external audit programs, Annual product reviews and Quality management reviews for Mylan
  • Manage and Maintain the site Vendor Management System
  • Support the quality organisation to meet the needs of the growing business; using technical expertise, skills knowledge and experience as required to resolve problems and share knowledge
  • Review and approve suppliers / service providers including supporting with audits of critical suppliers where required
  • Support the Quality Manager with hosting external audits and regulatory inspections
  • May act as principal project quality lead for new and existing Mylan projects providing advice and guidance to operational teams with support and guidance from the Quality Manager
  • Create, maintain and deliver training in quality related topics to Mylan personnel
  • Support the Quality Assurance team in preparation of monthly/quarterly/annual reports to be submitted to senior management and Mylan departments to ensure visibility of QMS requirements and performance including the compilation of quality metrics to facilitate monitoring and management of the Mylan Quality System
Desired Qualifications
  • Experience of sterile manufacturing desirable but not essential
  • Experience of TrackWise or similar electronic document management systems is highly desirable

Viatris provides a wide range of healthcare products that combine generic and brand-name medicines to meet global health needs. Their extensive portfolio includes high-quality medicines that address various health challenges, from acute conditions to chronic diseases, ensuring access to essential treatments for people at every stage of life. Viatris operates a global supply chain that allows them to deliver these medicines efficiently to approximately 1 billion patients worldwide. What sets Viatris apart from its competitors is its unique ability to bridge the gap between generics and brands, along with its commitment to making healthcare accessible on a large scale. The company's goal is to empower individuals to live healthier lives by providing the necessary medications and support throughout their health journeys.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris can leverage digital health trends to expand telemedicine and remote monitoring services.
  • The rise of value-based healthcare aligns with Viatris' focus on patient outcomes and cost-effectiveness.
  • Expansion in emerging markets offers Viatris opportunities to increase market presence and reach.

What critics are saying

  • Increased competition from low-cost generics could erode Viatris' market share.
  • Patent expirations in 2025 may lead to revenue loss from generic competition.
  • Ongoing opioid litigation could result in financial liabilities and reputational damage.

What makes Viatris unique

  • Viatris bridges the gap between generics and brands, offering a unique healthcare approach.
  • The company has a diverse portfolio, supplying medicines to 1 billion patients annually.
  • Viatris' global supply chain is designed to reach patients worldwide efficiently.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Feb 27th, 2025
Viatris Maintains Dividend Policy For 2025 And Announces Quarterly Dividend

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2025, to shareholders of record at the close of business on March 10, 2025. This marks the fifth consecutive year the Company has paid a dividend.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

INACTIVE